HC Wainwright & Co. Reiterates Buy on Spero Therapeutics, Maintains $7 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Spero Therapeutics (NASDAQ:SPRO) and maintained a price target of $7.
August 06, 2024 | 11:06 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Spero Therapeutics (NASDAQ:SPRO) and maintained a price target of $7.
The reiteration of a Buy rating and maintenance of a $7 price target by HC Wainwright & Co. is a positive signal for investors, likely boosting short-term confidence and potentially driving the stock price up.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100